Stock Track | Verona Pharma Shares Plunge Despite Solid Q3 Results

Stock Track11-04

Shares of Verona Pharma plc (NASDAQ: VRNA) experienced a pre-market plunge of 5.03% on November 4, 2024, despite reporting solid third-quarter financial results and providing a positive corporate update.

In its Q3 2024 earnings report, Verona Pharma announced a net sales of $5.6 million for its recently launched product Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The company reported strong adoption from healthcare professionals, with more than 2,200 unique prescribers and over 5,000 prescriptions filled across a broad range of COPD patients.

Despite the positive launch and pipeline updates, the biopharmaceutical company posted a wider net loss of $43.0 million for the third quarter, compared to a net loss of $14.7 million in the same period last year. The increased loss was primarily attributed to higher research and development expenses, as well as selling, general, and administrative expenses related to the commercial launch of Ohtuvayre.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1122444632?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-04 22:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122444632","market":"hk","top_or_hot":-1,"title":"Stock Track | Verona Pharma Shares Plunge Despite Solid Q3 Results","media":"Stock Track","content":"<p>Shares of Verona Pharma plc (NASDAQ: VRNA) experienced a pre-market plunge of 5.03% on November 4, 2024, despite reporting solid third-quarter financial results and providing a positive corporate update.</p>\n\n<p>In its Q3 2024 earnings report, Verona Pharma announced a net sales of $5.6 million for its recently launched product Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The company reported strong adoption from healthcare professionals, with more than 2,200 unique prescribers and over 5,000 prescriptions filled across a broad range of COPD patients.</p>\n\n<p>Despite the positive launch and pipeline updates, the biopharmaceutical company posted a wider net loss of $43.0 million for the third quarter, compared to a net loss of $14.7 million in the same period last year. The increased loss was primarily attributed to higher research and development expenses, as well as selling, general, and administrative expenses related to the commercial launch of Ohtuvayre.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Verona Pharma Shares Plunge Despite Solid Q3 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Verona Pharma Shares Plunge Despite Solid Q3 Results\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-04 22:20 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Verona Pharma plc (NASDAQ: VRNA) experienced a pre-market plunge of 5.03% on November 4, 2024, despite reporting solid third-quarter financial results and providing a positive corporate ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRNA","symbol_name":"维罗纳制药","start_time":0,"source_url":"","article_id":"1122444632","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122444632","pubTimestamp":1730730022,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Verona Pharma plc  experienced a pre-market plunge of 5.03% on November 4, 2024, despite reporting solid third-quarter financial results and providing a positive corporate update.In its Q3 2024 earnings report, Verona Pharma announced a net sales of $5.6 million for its recently launched product Ohtuvayre  for the maintenance treatment of chronic obstructive pulmonary disease . The company reported strong adoption from healthcare professionals, with more than 2,200 unique prescribers a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRNA":"维罗纳制药"},"translate_title":"尽管第三季度业绩稳健，维罗纳制药股价仍暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRNA":1},"content_text":"Shares of Verona Pharma plc (NASDAQ: VRNA) experienced a pre-market plunge of 5.03% on November 4, 2024, despite reporting solid third-quarter financial results and providing a positive corporate update.\nIn its Q3 2024 earnings report, Verona Pharma announced a net sales of $5.6 million for its recently launched product Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The company reported strong adoption from healthcare professionals, with more than 2,200 unique prescribers and over 5,000 prescriptions filled across a broad range of COPD patients.\nDespite the positive launch and pipeline updates, the biopharmaceutical company posted a wider net loss of $43.0 million for the third quarter, compared to a net loss of $14.7 million in the same period last year. The increased loss was primarily attributed to higher research and development expenses, as well as selling, general, and administrative expenses related to the commercial launch of Ohtuvayre.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122444632"}